Reckitt Q3 2025: volume-led growth, confident guidance, and tidy execution
Reckitt posted a strong third quarter, with Group like-for-like (LFL) net revenue up 7.0% to £3,611m. The quality of growth improved too: volumes did more of the lifting. Group volumes rose 4.2% with price/mix up 2.8%.
The engine room was Core Reckitt – the consumer health and hygiene portfolio – where LFL growth hit 6.7% on a neat balance of volume (+3.4%) and price/mix (+3.3%). Management reiterated full-year guidance and sounded confident about delivery.
Key numbers that matter
| Metric (Q3 2025 unless stated) | Reported |
|---|---|
| Group net revenue (IFRS) | £3,611m |
| Group LFL growth | +7.0% (volume +4.2%, price/mix +2.8%) |
| Core Reckitt LFL growth | +6.7% to £2,603m |
| Emerging Markets LFL | +15.5% to £1,080m |
| Europe LFL | +0.8% to £865m |
| North America LFL | +1.3% to £658m |
| Mead Johnson Nutrition LFL | +22.0% to £529m |
| Essential Home LFL | -4.9% to £479m |
| YTD Group LFL | +3.3% on £10,591m revenue (IFRS -0.3% after FX) |
| Share buyback | £1.0bn programme; first £250m tranche completed |
| FY 2025 Group LFL guidance | +3% to +4% (maintained) |
| Other guidance | Adj. net finance expense £350m-£370m; tax ~25%; capex 3%-4% of revenue |
Regional performance: Emerging Markets do the heavy lifting
Emerging Markets: double-digit and broad-based
Emerging Markets were the standout, up 15.5% LFL to £1,080m with a healthy split of volume (+7.4%) and price/mix (+8.1%). China delivered broad-based double-digit growth across Dettol, Durex, Veet, Intima and VMS lines, aided by new product variants and upgraded formulas.
India’s sell-in was muted in Q3 due to a GST regime change that shifted orders into Q4, but YTD LFL remains high single digit. Latin America was mixed: softer Brazil offset by growth in Mexico. Management also called out double-digit growth in smaller, high-potential markets like Indonesia, Malaysia and Colombia.
Europe: back to growth, volumes improving
Europe eked out 0.8% LFL growth to £865m despite a tough pricing backdrop, with volume down 0.5% but improving sequentially from Q1 (-4.7%) and Q2 (-1.9%). Premiumisation helped, notably in Finish Ultimate Plus, while Self Care brands Gaviscon and Nurofen performed well.
Category growth across the area was broadly flat, and Western Europe remains a tricky pricing environment. Still, four of six regions grew LFL in the quarter – progress.
North America: steady outside seasonal OTC
North America returned to LFL growth at 1.3% to £658m, volume +2.3% and price/mix -1.0%. Excluding seasonal over-the-counter (OTC) cold and flu, the region posted mid single-digit growth, led by Lysol momentum (including Air Sanitiser and Laundry Sanitiser), resilient Finish and a good showing from Neuriva.
Seasonal OTC was the drag, declining mid single digit as the category lapped a Covid-driven spike in Q3 2024. The transition to a PE-free Mucinex Sinus formulation “landed as anticipated”, setting up for the winter season.
Category trends: health and intimacy outpace the rest
Self Care: strong ex-seasonal OTC
Self Care grew 5.6% LFL to £859m (volume +1.2%, price/mix +4.4%). Strip out seasonal OTC and growth was a punchier 12.3% LFL, powered by VMS in China plus Gaviscon and favourable Nurofen phasing in Europe. Seasonal OTC declined 3.4% LFL in the quarter and is down 7.8% YTD.
Germ Protection: volumes are back
Germ Protection rose 9.2% LFL to £838m, with most of that from volume (+8.2%). Dettol had another double-digit quarter led by China and MENARP, and Lysol posted high single-digit volume-led growth in North America.
Intimate Wellness: premiumisation at work
Intimate Wellness jumped 13.5% LFL to £375m, with price/mix a hefty +10.9% and volume +2.6%. Durex grew strongly in China, ASEAN and MENARP, aided by innovations like Durex Intensity and Benzocaine upgrades. Intima continues to resonate in China, with LFL revenue more than doubling YTD.
Household Care: holding the line
Household Care was flat to modestly positive at +0.2% LFL to £531m. Finish grew in Emerging Markets and held up in North America, while Europe remained challenging. Vanish was mixed – up mid single digit in Emerging Markets and down mid single digit in Europe.
Non-core segments: Mead Johnson rebounds, Essential Home weighs
Mead Johnson Nutrition: bounce after last year’s tornado impact
Mead Johnson delivered 22.0% LFL growth to £529m, split between volume (+12.4%) and price/mix (+9.6%). This partly reflects an easy comparator after the July 2024 tornado destroyed its primary U.S. warehouse. YTD LFL is +4.0%, with international business growing low single digit in Q3 alongside North America’s recovery.
Essential Home: softness in Brazil pest and U.S. Air Care
Essential Home declined 4.9% LFL to £479m. Volumes were slightly positive (+0.6%) but price/mix was negative (-5.5%). Europe performed “as expected”, but Brazil’s pest category remained weak and U.S. Air Care softened. YTD LFL is -6.0% as the business heads for divestment, which Reckitt expects to complete by 31 December 2025.
Guidance, profit shape and capital returns
Full-year guidance is unchanged: Group LFL growth of 3% to 4%; Core Reckitt above 4%; Mead Johnson Nutrition low-to-mid single-digit growth; Essential Home a mid single-digit decline (trimmed from low single-digit decline previously).
The Fuel for Growth programme is expected to drive adjusted operating profit ahead of net revenue growth, and management expects another year of adjusted diluted EPS growth. On capital allocation, the £1 billion share buyback started on 28 July 2025; the first £250m tranche has been completed. Technical guidance: adjusted net finance expense £350m to £370m, adjusted effective tax rate around 25%, and capex at 3% to 4% of net revenue.
My take: quality improving, but a few watch-outs
- Positive – volume-led recovery: Group volume up 4.2% and Core Reckitt volume up 3.4% is exactly what investors wanted after price-led growth. It suggests consumer demand for Powerbrands remains resilient.
- Positive – Emerging Markets momentum: 15.5% LFL with strong contributions from China and share gains across Dettol, Durex, Veet and VMS underline the portfolio’s EM strength.
- Positive – innovation paying off: New products in Self Care and Intimate Wellness are driving price/mix, particularly Durex Intensity and the Chinese product upgrades.
- Neutral – North America mix: Ex-seasonal OTC is healthy, but the seasonal category remains a swing factor into Q4. The PE-free Mucinex transition de-risks the brand from a regulatory and consumer perspective.
- Negative – Essential Home drag: LFL -4.9% reflects tough Brazil pest and U.S. Air Care. The planned divestment by year-end should tidy up the portfolio, but near-term optics may remain soft.
- Negative – FX and finance costs: A 2.4% FX headwind muted reported growth in Q3, and higher adjusted net finance expense (£350m-£370m) plus a higher tax rate (~25%) are worth noting for EPS translation.
What to watch next
- Q4 seasonal OTC sell-through: category dynamics after last year’s Covid spike will drive the Self Care exit rate.
- Execution in China and India: momentum is strong; India should normalise after the GST-related order shift into Q4.
- Essential Home disposal: completion by 31 December 2025 is the goal. Proceeds and any transitional arrangements are not disclosed.
- Delivery on “profit ahead of sales”: management expects adjusted operating profit to outgrow revenue – helpful for margin narrative into 2026.
Quick jargon buster
- Like-for-like (LFL): growth at constant exchange rates, excluding acquisitions and disposals.
- Price/mix: the impact of pricing changes and the mix of products sold.
- Seasonal OTC: cold and flu brands that skew to the winter season.
Overall, this was a clean quarter: volumes up, innovations landing, Emerging Markets firing, and guidance intact. There are moving parts – seasonal OTC, FX and Essential Home – but the trajectory in Core Reckitt looks encouraging. For long-term holders, this reads as steady execution with strategic housekeeping well underway.
